3d illustration of rotating DNA

Press releases

British Patient Capital invests in Microbiotica

7 March 2022: British Patient Capital has invested in Microbiotica, a personalised medicine specialist, as part of a £50m Series B funding round.

The investment has been made via Future Fund: Breakthrough, our £375m programme where we co-invest with private sector investors in innovative, R&D-intensive UK companies. The round was led by Flerie Invest and Tencent, and included Cambridge Innovation Capital, IP Group and Seventure Partners.

Headquartered at the Chesterford Research Park near Cambridge, Microbiotica has developed technology which uses the body’s trillions of resident bacteria – known as the microbiome – to discover and develop therapeutic medicines and biomarkers for a range of disorders and diseases. The company’s current areas of focus are cancer immunotherapy and inflammatory bowel disease and it has established major clinical and academic partnerships in these areas.

Judith Hartley, CEO of British Patient Capital, said: “Microbiotica is a highly innovative UK company operating in the very important field of microbiome biology. Through its bioinformatics platform, it is generating therapeutic treatments targeting immuno-oncology and ulcerative colitis. It has a number of drug development programmes that are progressing to clinical trials. British Patient Capital, through our Future Fund: Breakthrough programme, is proud to support this world-class team as they continue to explore and commercialise this exciting new area of medicine.”

Mike Romanos, Co-Founder and CEO of Microbiotica, said: “This major fundraise is a substantial validation of both our team and our world-leading technology. We are fortunate to have the support from new and current investors who have recognised the importance of the microbiome’s therapeutic potential and Microbiotica’s unique capabilities. With this additional investment, we will be able to conduct clinical trials with our lead products in immuno-oncology and ulcerative colitis. We will also expand our portfolio of microbiome-based products which have the potential to benefit patients globally.”


About British Patient Capital

British Patient Capital is the trading name of British Patient Capital Limited, a wholly-owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank. It forms part of the British Business Bank’s plc’s commercial arm.

Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large scale businesses. Launched in June 2018, British Patient Capital has £2.5bn to invest over 10 years in venture and venture growth capital to support high growth potential innovative UK businesses in accessing the long-term financing they require to scale up. Find out more at britishpatientcapital.co.uk.

British Business Bank plc and its subsidiary entities are not banking institutions and do not operate as such. They are not authorised or regulated by the Prudential Regulation Authority (PRA) or the Financial Conduct Authority (FCA). A complete legal structure chart for British Business Bank plc and its subsidiaries can be found on the British Business Bank plc website.

British Patient Capital makes commitments and invests on its own behalf and on behalf of third-party investors whose investments British Patient Capital manages.

This investment from British Patient Capital does not amount to any endorsement or warranty from British Patient Capital, the British Business Bank plc, or the government of the UK.

About Microbiotica

Microbiotica is a leading player in the field of microbiome-based therapeutics, biomarkers and targets. The Company is building a growing pipeline of differentiated products based on high quality clinical datasets and unique bacterial signatures that drive biology, identified by its proprietary platform.

Consisting of the leading microbiome Reference Genome Database, Culture Collection, mass culturing technology (Personalised Bacterial Bank) and proprietary AI tools, Microbiotica’s platform enables unrivalled strain-level microbiome analysis linked to patient phenotypes. The Company’s current therapeutic areas of focus are immuno-oncology and IBD and it has established major clinical and academic partnerships in these areas.

Spun out of the Sanger Institute in 2016, the Company is based at Chesterford Research Park near Cambridge, UK. Microbiotica’s investor syndicate includes British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners, and Tencent.

For more information


British Patient Capital team at Lansons